Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (bolt study): Report 1

Retina

Volumn 30, Issue 5, 2010, Pages 781-786

  Michaelides, Michel ^a,b   Fraser Bell, Samantha ^a   Hamilton, Robin ^a   Kaines, Andrew ^a   Egan, Catherine ^a   Bunce, Catey ^a   Peto, Tunde ^a   Hykin, Phil ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bevacizumab; Clinically significant macular edema; Diabetes; Diabetic macular edema; Fundus fluorescein angiography; Laser therapy; Macula; Macular perfusion; Prospective randomized trial

Indexed keywords

BEVACIZUMAB;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE EXACERBATION; EYE BLOOD FLOW; EYE FUNDUS; HUMAN; INTERMETHOD COMPARISON; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA CAPILLARY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINA ISCHEMIA; TREATMENT DURATION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INJECTIONS; LASER COAGULATION; MACULAR EDEMA; PROSPECTIVE STUDIES; RETINAL VESSELS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77952271206     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181d2f145     Document Type: Article

References (21)

1. Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. Eye 2008;22:905-911.
2. Paulus YM, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics 2009;64:16-20.
3. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008;88:1254-1264.
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
5. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-713.
6. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497-503.
7. Hirai FE, Knudtson MD, Klein BE, Klein R. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145:700-706.
8. Klein R, Moss SE, Klein BE, Gutierrez P, Mangione CM. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol 2001;119:733-740.
9. Matza LS, Rousculp MD, Malley K, Boye KS, Oglesby A. The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. Health Qual Life Outcomes 2008; 6:95.
10. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796-1806.
11. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
12. Kaines A, Fraser-Bell S, Michaelides M, Egan C, Hykin P. Diabetic macular oedema: a prospective randomised trial of management with intravitreal bevacizumab (Avastin) versus conventional laser therapy: a description of methodology. Invest Ophthalmol Vis Sci 2008; 49: E-Abstract 3505.
13. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:807-822.
14. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999;155:421-428.
15. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
16. Ameri H, Chader GJ, Kim JG, Sadda SR, Rao NA, Humayun MS. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci 2007;48:5708-5715.
17. Chung EJ, Roh MI, Kwon OW, Koh HJ. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 2008;28:957-963.
18. Wong LJ, Desai RU, Jain A, et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 2008;28:1151-1158.
19. Rouvas AA, Papakostas TD, Ladas ID, Vergados I. Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2008;246:315-318.
20. Lee CS, Koh HJ. Multiple retinal haemorrhages in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy. Acta Ophthalmol 2008;86:812-813.
21. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28:1053-1060.